Skip to main content

Sound Advice: May 4, 2022

Are Health Care Stocks on the Mend? 

The two sectors that have provided the highest returns in years past have been technology and health care.  We discussed technology last week.  This week it’s health care’s turn and even though the pandemic has brought a renewed focus on health care, most of these stocks have also experienced weakness this year.

Let’s focus on Johnson & Johnson, Pfizer, and Moderna since they have been the leaders in development of Covid vaccines.  Although all three have been in high gear turning out hundreds of millions of doses, their stock market performances have been anything but consistent.

Last year, it was estimated that Pfizer and Moderna had over $50 billion in sales from their Covid-19 vaccines.  Johnson & Johnson had $2.4 billion in Covid vaccine revenues.   

Given those numbers, one might well have expected a significant upsurge in the shares of these companies.  But the net result was anything but.  For 2022 to date, J&J shares have risen 5.4% in contrast to Pfizer and Moderna, which dropped 18% and 43%, respectively, since January 1st.

Even if we measure the shares’ market performance over the latest year, the returns have been less than stellar.  The best showing was from Pfizer shares, which climbed 25.2%.  J&J and Moderna were down 1.5% and 20.3%, respectively, over the same period.

For health care stocks generally, the picture has been no better.  The leading exchange-traded funds from iShares and SPDR, which hold wide baskets of these stocks, both lost ground over the period.  The good news, however, is that they did much better than tech stocks.

Over the last two decades, the average returns from tech stocks have been more than double those of health care stocks and more than triple that of the market generally.  But don’t forget, the gains from tech stocks came along with considerable fluctuation.  Increases from the health care stocks were well above those of the market generally with far less dramatic volatility.

N. Russell Wayne, CFP®

Sound Asset Management Inc.

Weston, CT  06883

203-222-9370

www.soundasset.com

www.soundasset.blogspot.com 

Any questions?  Please contact me at nrwayne@soundasset.com

Comments

Post a Comment

Popular posts from this blog

Sound Advice: July 16, 2025

Fixed annuities are poor investments Fixed annuities are often criticized as poor investments for several reasons, despite their reputation for providing stable, predictable income.  Here are the key drawbacks and concerns:   High Fees and Commissions Internal Fees:  Fixed annuities can carry a range of fees, including administrative charges, mortality expense risk fees, and rider fees. These can add up to 2%–4% per year, significantly eroding returns over time. Commissions:  Sales agents and financial advisors often receive high commissions for selling annuities—sometimes as much as 5%–8% of the invested amount. This creates a financial incentive for advisers to recommend them, even when they may not be the best fit for the client. Comparison to Other Investments:  Mutual funds and ETFs typically have much lower fees and commissions, making them more cost-effective for long-term growth. Limited Growth a...
Post a Comment
Read more

Sound Advice: October 8, 2025

How many investors have outperformed the stock market over the last 20 years? Very few investors have outperformed the stock market over the past 20 years.   Data shows that only about 6% to 8% of actively managed equity funds in the U.S. beat the market over this period, with the vast majority—over 90%—underperforming the S&P 500 or equivalent broad indexes. Percentage of Investors Beating the Market Only 8% of equity funds investing in large companies managed to outperform the market over a recent 20-year span. About 94% of all domestic funds underperformed the S&P 1500 Composite Index from 2005-2024. Over shorter timeframes (5-10 years), typically fewer than 15-20% of fund managers beat the S&P 500, and performance persistence is rare. Why It Is Rare The S&P 500’s high returns have proven immensely difficult to beat, especially as indexing has become popular and markets have ...
Post a Comment
Read more

Sound Advice: January 15, 2025

Why investors shouldn't pay attention to Wall Street forecasts   Investors shouldn't pay attention to Wall Street forecasts for several compelling reasons: Poor accuracy Wall Street forecasts have a terrible track record of accuracy. Studies show that their predictions are often no better than random chance, with accuracy rates as low as 47%   Some prominent analysts even perform worse, with accuracy ratings as low as 35% Consistent overestimation Analysts consistently overestimate earnings growth, predicting 10-12%                 annual growth when the reality is closer to 6%.   This overoptimism can                 lead investors to make overly aggressive bets in the market. Inability to predict unpredictable events The stock market is influenced by numerous unpredictable factors, including geopolitical events, technological changes, and company-specific news.   Anal...
Post a Comment
Read more